Recognition and Management of Transfusion-Associated Circulatory Overload

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Transfusion-Associated Circulatory Overload (TACO) is a potentially fatal complication arising from the recipient's inability to accommodate infused blood product volume, exacerbated by transfusion-specific factors beyond simple volume expansion. Key risk factors include pre-existing cardiac disease, acute kidney injury, and preceding hemorrhagic shock, which create a state of "volume incompliance."

• Clinical recognition hinges on identifying signs of respiratory distress (tachypnea, increased effort, crackles) and circulatory overload (tachycardia, hypertension, jugular distension) during or within six hours post-transfusion. A weight gain exceeding 2% of baseline body weight is a critical objective indicator supporting a TACO diagnosis.

• Immediate management involves discontinuing the transfusion, administering supplemental oxygen, and initiating therapy with loop diuretics (e.g., furosemide) to reduce preload and promote diuresis. Hypertension may necessitate vasodilator therapy, while severe hypoxemia may require mechanical ventilation.

• Differentiating TACO from transfusion-related acute lung injury (TRALI) is crucial, as treatments diverge. TACO typically presents with hypertension and responds to diuresis, whereas TRALI is characterized by normotension to hypotension and requires supportive care without volume removal.

• Prevention in high-risk patients involves transfusing at a slower rate and in smaller aliquots, with meticulous monitoring of respiratory rate, effort, blood pressure, and auscultation. Prophylactic diuretics are generally not recommended due to potential complications in volume-depleted patients.

• TACO can manifest with distinct failure modes including acute pulmonary edema, biventricular failure with systemic congestion, or cardiogenic shock. Delayed recognition during anesthesia or concurrent TRALI represent significant challenges requiring specialized management strategies.

Transfusion-associated circulatory overload (TACO) is a potentially fatal complication of blood product administration in dogs and cats. It results from the interplay between the volume of blood products delivered and the recipient's capacity to tolerate that volume. This article provides the practicing veterinarian with a framework for recognizing TACO early, distinguishing it from other transfusion reactions, and managing affected patients. It addresses the pathophysiology that underlies the condition, the risk factors that predispose individual patients, the clinical features that should trigger diagnostic suspicion, and the treatment strategies supported by current evidence.

The clinical question this article answers is direct: when a dog or cat deteriorates during or shortly after a transfusion, how does the clinician determine whether TACO is the cause, and what actions follow that determination? The answer requires integrating knowledge of cardiovascular physiology, transfusion medicine, and fluid therapy principles. The reader is assumed to be comfortable with basic hemodynamic monitoring and the routine conduct of blood transfusions in small animal practice.

At a Glance

Pathophysiology of TACO

The traditional view of TACO held that it was simply a matter of transfusing too much volume too quickly into a patient whose cardiovascular system could not cope. That model is incomplete. Experimental work in a validated two-hit rat model demonstrated that volume-incompliant animals, those with myocardial infarction or acute kidney injury, developed significantly greater increases in left ventricular end-diastolic pressure after red blood cell transfusion than after an equal volume of crystalloid. In control animals without a first hit, there was no difference between transfusion and crystalloid infusion. This finding indicates that TACO is not equivalent to fluid overload from crystalloids, and that the transfusion itself contributes to the hemodynamic burden through mechanisms beyond simple volume delivery.

The two-hit model has been extended to examine whether the type of blood product matters. In rats with heart failure, transfusion of standard volume lyophilized plasma, volume-reduced lyophilized plasma, and solvent-detergent pooled plasma all increased left ventricular end-diastolic pressure. Notably, the hyperoncotic volume-reduced product produced the greatest elevation, suggesting that oncotic properties and product composition influence the circulatory response independently of infused volume.

A separate large animal study in swine examined whether massive transfusion alone could reproduce the respiratory distress of TACO. Pigs receiving crystalloid, hydroxyethyl starch, or allogeneic blood at volumes equivalent to 100% of blood volume did not develop significant reductions in the PaO2/FiO2 ratio. However, animals subjected to hemorrhagic shock prior to allogeneic blood transfusion did develop respiratory distress. The authors observed that blood transfusion after hemorrhagic shock expanded the blood volume, whereas over-transfusion alone did not. This work supports the concept that a preceding insult, in this case hemorrhagic shock, primes the recipient for TACO.

The clinical implication of these experimental findings is that TACO risk cannot be predicted solely by calculating transfusion volume against body weight. The recipient's cardiovascular reserve, renal function, and recent hemodynamic history all determine whether a given transfusion will be tolerated. A patient with compensated mitral valve disease may tolerate a transfusion that would precipitate pulmonary edema in a patient with acute kidney injury, even when the volumes are identical.

Volume Incompliance as the Central Defect

Volume incompliance describes a state in which the cardiovascular system cannot accommodate an acute increase in intravascular volume without a disproportionate rise in filling pressures. The concept is borrowed from human transfusion medicine and has direct relevance to veterinary patients. Causes of volume incompliance in dogs and cats include systolic or diastolic myocardial dysfunction, valvular disease, chronic hypertension, renal insufficiency with impaired sodium and water excretion, and pulmonary hypertension.

The two-hit animal model provides a mechanistic basis for this clinical observation. Animals with myocardial infarction or acute kidney injury, but not healthy controls, met clinical criteria for TACO after transfusion. The first hit, the underlying cardiac or renal disease, created a state of reduced compliance. The second hit, the transfusion, then produced circulatory overload that an otherwise healthy animal would have tolerated.

This framework changes how the clinician should approach transfusion in at-risk patients. instead of asking only "how much blood does this patient need," the clinician must also ask "how much volume can this patient's cardiovascular system accept, and at what rate?" The answer to the second question determines the transfusion rate, the need for concurrent diuretic therapy, and the intensity of monitoring required.

Risk Factors and Patient Identification

Risk stratification begins before the blood product is hung. Cardiac disease is the most obvious risk factor, but it is not the only one. The experimental literature identifies acute kidney injury and preceding hemorrhagic shock as independent contributors to TACO risk. In the swine model, hemorrhagic shock prior to transfusion was a detrimental risk factor for subsequent respiratory distress, even though the transfusion volume was identical to that given to non-shocked animals.

Renal disease impairs the kidney's ability to excrete the sodium and water load delivered with blood products. This is particularly relevant in cats, where chronic kidney disease is common and often coexists with anemia of renal disease. The cat that presents with pale mucous membranes, azotemia, and a hematocrit of 15% is a classic TACO candidate. The clinician must weigh the benefit of transfusion against the near-certainty that the patient's kidneys cannot handle the volume.

Other risk factors include pre-existing respiratory disease, obesity, and age. The authors of the AAHA/AAFP fluid therapy guidelines emphasize that monitoring and rate adjustment should be individualized to the patient's cardiovascular and renal status. A patient with any of these risk factors should receive blood products at a slower rate, with more frequent reassessment, and with a lower threshold for intervention.

Clinical Recognition and Diagnostic Reasoning

TACO typically manifests during the transfusion or within six hours of its completion. The earliest signs are often subtle: a mild increase in respiratory rate, a change in respiratory effort, or restlessness. These signs may be attributed to the patient's underlying disease, particularly if the patient was anemic and tachycardic before the transfusion began. The clinician must maintain a high index of suspicion and compare the patient's current status against a baseline established immediately before transfusion.

Progressive signs include tachypnea, increased inspiratory effort, crackles on thoracic auscultation, and a wet cough. Jugular venous distension may be visible in dogs, though it is more difficult to assess in cats. Tachycardia is common, and hypertension may be present. The patient may become agitated or orthopneic. In severe cases, cyanosis and collapse occur.

The differential diagnosis includes transfusion-related acute lung injury (TRALI), febrile non-hemolytic transfusion reactions, and acute hemolytic reactions. TRALI is distinguished from TACO primarily by the absence of volume overload signs such as hypertension and jugular distension, and by the presence of fever and leukopenia in some cases. The distinction matters because the treatments differ: TACO responds to diuresis, while TRALI requires supportive care without volume removal. The Association of Veterinary Hematology and Transfusion Medicine has published consensus definitions for transfusion reactions, and the clinician should be familiar with these criteria when classifying a reaction.

Body weight is the single most useful objective measurement. A weight gain of more than 2% from the pre-transfusion baseline supports a diagnosis of TACO. The clinician should weigh the patient before transfusion and again at the first sign of respiratory deterioration. This requires a scale that can accommodate the patient without stress, and a technician who can obtain the weight quickly.

Monitoring Strategies to Detect TACO Early

The monitoring plan for a transfusion should be determined by the patient's risk profile. For a young, healthy dog with no cardiovascular disease receiving a slow transfusion for trauma-related anemia, standard monitoring may suffice. For a cat with chronic kidney disease and suspected cardiac disease, the monitoring plan must be more intensive.

The AAHA/AAFP fluid therapy guidelines recommend regular reassessment of body weight, respiratory rate and effort, heart rate, and blood pressure during fluid administration. These same principles apply to blood products. The clinician should establish a baseline for each parameter immediately before transfusion and then reassess at intervals no longer than 15 to 30 minutes during the transfusion. In high-risk patients, more frequent assessment is warranted.

Pulse oximetry can detect early desaturation, though it may be unreliable in hypotensive or vasoconstricted patients. Blood pressure measurement is essential, as hypertension is a distinguishing feature of TACO. Thoracic auscultation should be performed at each reassessment, with attention to the development of crackles or a change in the character of lung sounds.

The decision to slow or stop a transfusion should be made proactively, not reactively. If the respiratory rate increases by more than 20% from baseline, the transfusion should be paused and the patient reassessed. If there is any doubt about the cause of deterioration, the transfusion should be stopped. A unit of blood product that is not transfused can be returned to the blood bank if it has not been out of controlled storage for too long, whereas a patient with fulminant pulmonary edema cannot be easily rescued.

Immediate Interventions and Resuscitation

When TACO is suspected, transfusion must be stopped immediately. The intravenous catheter should be kept patent with a minimal-volume crystalloid infusion at a rate that does not contribute further to volume loading. The patient is placed in sternal or upright recumbency to reduce thoracic venous return where tolerated. Oxygen is delivered by mask, flow-by, or nasal cannula at the highest fraction achievable without causing patient distress. Patients with severe respiratory effort may require sedation to lower oxygen consumption, but the sedative choice must avoid further cardiovascular depression.

Furosemide is the primary pharmacologic intervention. The goal is to reduce preload through venodilation and diuresis. Response is assessed by urine output, respiratory rate and effort, and serial body weight. A patient that does not produce urine within 30 to 60 minutes of furosemide administration has either inadequate renal perfusion or insufficient dose. Current formulary references should be consulted for dosing, as published ranges vary with species and renal status. Cats are more sensitive to the ototoxic and nephrotoxic effects of loop diuretics, so dose escalation should be more cautious in this species.

Vasodilator therapy is indicated when hypertension accompanies the volume overload. Nitroprusside or nitroglycerin can reduce afterload and preload, but both require close blood pressure monitoring. Hypotension after vasodilator use in a TACO patient is a poor prognostic sign and may indicate concurrent cardiogenic shock. Positive inotropic support is reserved for patients with documented systolic dysfunction, which is uncommon in the acute TACO presentation.

Ventilatory Support and Airway Management

Patients with progressive hypoxemia despite supplemental oxygen may require mechanical ventilation. The decision to intubate is based on clinical trajectory instead of a single blood gas value. Worsening respiratory rate, declining mentation, or a PaO2 below 60 mm Hg on high-flow oxygen are reasonable thresholds. Positive pressure ventilation recruits collapsed alveoli and reduces venous return, which can be beneficial in TACO. However, the same reduction in preload can precipitate hypotension in a volume-depleted or vasoplegic patient. Ventilator settings should therefore be adjusted with continuous blood pressure monitoring.

Non-invasive ventilation is rarely feasible in dogs and cats because of facial conformation and patient tolerance. Nasal continuous positive airway pressure has been described in larger dogs but requires significant technical support. Most veterinary patients with severe TACO will require endotracheal intubation and volume-controlled or pressure-controlled ventilation.

Differentiating TACO from Other Respiratory Complications

The distinction between TACO and transfusion-related acute lung injury (TRALI) is clinically important because the treatments diverge. TACO is a volume problem, TRALI is an inflammatory permeability problem. The two can coexist, and the diagnostic separation is not always clean. The following table summarizes the features that help prioritize one diagnosis over the other.

A single dose of furosemide that produces clinical improvement strongly supports TACO. Lack of response should prompt reconsideration of TRALI, aspiration pneumonitis, or progression to acute respiratory distress syndrome. Thoracic radiographs may show alveolar infiltrates in both conditions, but cardiomegaly and pulmonary venous distension favour TACO. Point-of-care ultrasound of the lungs and heart can provide the same information more rapidly and without moving the patient.

Monitoring Parameters and Escalation Criteria

Monitoring after the initial intervention serves three purposes: confirming the diagnosis, tracking response to therapy, and detecting deterioration before it becomes irreversible. The following parameters should be recorded at baseline and at regular intervals during the first 24 hours after recognition.

The frequency of monitoring should be adjusted to the severity of the presentation. A patient with mild tachypnoea that responds to a single furosemide dose may only require hourly checks. A patient with severe hypoxemia and hypotension requires continuous monitoring in an intensive care setting. The AAHA and AAFP fluid therapy guidelines emphasize that monitoring intensity should match the patient's cardiovascular reserve, not a fixed protocol.

Documentation and Communication

Every suspected TACO event should be documented in the medical record with the following elements: the time of transfusion start and stop, the volume and rate of blood product administered, the clinical signs that triggered suspicion, the interventions performed and their timing, and the patient's response. Photographs of the blood product label and administration set are useful for later review. The blood bank or product supplier should be notified if a component is suspected of contributing to the reaction, particularly if the same donor unit was split and administered to other patients.

The RECOVER Initiative guidelines note that structured communication during resuscitation reduces errors. The same principle applies to transfusion reactions. A brief handoff to the next shift should include the patient's current respiratory status, the cumulative furosemide dose, the urine output trend, and the plan for further monitoring. This is especially important in facilities where the transfusion was started by one clinician and the reaction is managed by another.

Prevention in High-Risk Patients

Prevention begins with identifying the volume-incompliant patient before transfusion. The two-hit model of TACO demonstrates that volume intolerance is the first hit and the transfusion itself is the second. Animals with heart failure or acute kidney injury develop higher left ventricular end-diastolic pressures after red blood cell transfusion than after an equal volume of crystalloid, suggesting that blood products carry a specific risk beyond simple volume expansion. This finding supports the clinical practice of transfusing high-risk patients more slowly and in smaller aliquots.

The MSD Veterinary Manual advises that patients with pre-existing cardiac or renal disease receive blood products at a reduced rate with more frequent monitoring. A practical approach is to administer the first 25% of the transfusion volume over twice the standard duration, then reassess respiratory rate, blood pressure, and lung auscultation before continuing. Prophylactic furosemide is not recommended as a routine measure because it can complicate volume assessment and may precipitate hypotension in a patient that is already volume-depleted from the underlying anemia.

Leukoreduction of blood products has been associated with a reduced incidence of TACO in human transfusion practice. A large retrospective study found that universal leukoreduction was followed by a 49% decrease in TACO cases per 100,000 components transfused. The mechanism is not fully understood, and the authors note that the finding generates hypotheses instead of proving causation. Veterinary blood banks increasingly offer leukoreduced products, and their use in high-risk patients is reasonable where available, although the evidence base in dogs and cats remains limited.

The decision to transfuse at all should be revisited in every high-risk patient. A patient with chronic anemia and compensated cardiovascular function may tolerate a hemoglobin concentration that would be unacceptable in an acutely bleeding patient. The AVMA practice resources emphasize that transfusion is a clinical decision based on the patient's oxygen delivery needs, not a laboratory value alone. Delaying transfusion while optimizing volume status and cardiac function may be the single most effective preventive measure for TACO.

Recognized Complications and Failure Modes

TACO can progress through several recognizable failure modes, each with distinct early findings. The first is acute pulmonary edema with preserved cardiac output, where tachypnoea and crackles develop before hypoxemia becomes severe. The second is biventricular failure with systemic congestion, recognized by jugular distension, hepatomegaly, and weight gain relative to the volume infused. The third is cardiogenic shock, where progressive myocardial stretch and reduced compliance cause hypotension and metabolic acidosis despite adequate or excessive preload.

A fourth failure mode is delayed recognition during sedation or anesthesia, where the patient cannot display dyspnoea and the only early clues are rising end-tidal carbon dioxide, falling compliance on mechanical ventilation, and progressive hypoxemia. A fifth is concurrent transfusion-related acute lung injury, which can coexist with TACO and requires different ventilatory and fluid strategies.

Early detection depends on trend recognition instead of single measurements. Serial body weight, respiratory rate, and pulse pressure variation identify volume accumulation before auscultatory changes appear. The two-hit model described by Klanderman and colleagues demonstrates that volume-incompliant subjects meet clinical TACO criteria in 92% of transfused cases versus 25% of fluid-infused controls, confirming that the transfusion itself, also the volume, drives the complication. This distinction matters clinically: a patient who tolerates crystalloid may still decompensate with blood products.

Common Errors and Corrective Actions

Less experienced clinicians often mistake early TACO for anaphylaxis or a febrile reaction. The distinction matters because anaphylaxis treatment includes adrenaline and fluid boluses, both of which worsen TACO. Check for fever, urticaria, and acute vomiting before treating for anaphylaxis. TACO typically presents with bradycardia or tachycardia without fever or cutaneous signs.

A second error is continuing the transfusion while treating the signs. The transfusion must stop immediately when respiratory distress develops, even before the diagnosis is confirmed. A third error is using furosemide alone without addressing the underlying volume incompliance. Diuresis removes fluid but does not correct the myocardial or renal dysfunction that caused the intolerance. The AAHA and AAFP fluid therapy guidelines emphasize that monitoring and rate adjustment are the primary preventive tools, with diuretics reserved for established overload.

A fourth error is attributing post-transfusion hypoxemia to the primary disease without considering TACO. Any respiratory deterioration within six hours of transfusion should trigger the TACO checklist until proven otherwise. A fifth error is failing to account for all volume sources. Blood products, crystalloid boluses, drug infusions, and flush solutions accumulate rapidly in a small patient.

Limitations of Current Evidence

The veterinary evidence base for TACO is limited. Most mechanistic data derive from rodent and swine models, and extrapolation to dogs and cats requires caution. The rat model by Klanderman and colleagues shows that red blood cell transfusion increases left ventricular end-diastolic pressure more than crystalloid in volume-incompliant animals, but the clinical relevance of this difference in spontaneously breathing patients remains uncertain. Similarly, the swine model by Masuda and colleagues suggests that preceding hemorrhagic shock sensitizes the lung to transfusion-related injury, but the study used massive transfusion volumes unlikely to be replicated in clinical practice.

Human data suggest that leukoreduction reduces TACO incidence by approximately 49%, but this finding has not been replicated in veterinary patients and the mechanism remains speculative. Expert opinion still differs on whether TACO is purely a hydrostatic phenomenon or whether inflammatory mediators in stored blood contribute independently. The practical consequence is that prevention strategies remain centerd on rate reduction and volume limitation, with no veterinary-specific evidence for leukoreduction, washing, or volume-reduced products. The study by Bulle and colleagues found that hyperoncotic volume-reduced plasma actually increased left ventricular end-diastolic pressure compared with standard plasma, cautioning against assuming that lower volume necessarily means lower cardiac strain.

Referral and Escalation Criteria

Referral to a specialist or intensive care facility is warranted when a patient requires mechanical ventilation, continuous positive airway pressure, or vasoactive support for more than a few hours. Patients with pre-existing cardiac disease, chronic kidney disease, or prior TACO episodes should be managed in settings where echocardiography and continuous monitoring are available.

Laboratory involvement is indicated when the diagnosis is uncertain, particularly to exclude hemolysis or sepsis as alternative causes. Serial lactate, blood gas analysis, and electrolyte monitoring guide resuscitation and diuretic therapy. The RECOVER guidelines provide structured approaches to post-arrest care if TACO progresses to cardiopulmonary arrest, including specific ventilation and drug protocols for dogs and cats.

Regulatory reporting obligations vary by jurisdiction. The AVMA provides practice resources that outline voluntary adverse event reporting systems for biological products, and clinicians should report suspected transfusion reactions to the product manufacturer and relevant national authority. The WOAH terrestrial animal health code does not address transfusion reactions directly, but clinicians in countries that follow WOAH standards should be aware of local pharmacovigilance requirements for biological products. When in doubt, report the reaction and document the clinical course thoroughly, as this information contributes to the limited veterinary hemovigilance data available.

Frequently Asked Questions

How do I manage TACO when I have no oxygen supplementation or mechanical ventilation available?

When advanced respiratory support is unavailable, prioritize immediate cessation or marked reduction of the transfusion rate, then administer a loop diuretic if cardiovascular status permits. Position the patient in sternal recumbency with the head elevated to reduce pulmonary venous congestion. Use manual or low-flow nasal oxygen if any source exists. Monitor perfusion, mentation, and respiratory effort continuously. If respiratory distress progresses despite diuretic therapy, consider partial phlebotomy of 5 to 10 mL/kg from a jugular catheter as a temporising measure, though this carries hypotension risk. The AAHA and AAFP fluid therapy guidelines emphasize that prevention through rate reduction and risk stratification is the most reliable strategy when monitoring and rescue resources are limited.

What should I document when a transfusion reaction is suspected?

Record the time of transfusion initiation, product type and volume, pre-transfusion vital parameters, and the exact time and nature of the change in patient status. Document the estimated infused volume at reaction onset, physical examination findings, and any interventions with their timing and response. Include a working differential list and the rationale for the TACO diagnosis versus alternative reactions. Note whether the reaction was reported to the blood product supplier or a hemovigilance program if one exists in your region. The AVMA practice resources provide guidance on professional record-keeping standards that support both clinical continuity and medicolegal defensibility.

How do I explain TACO to a client whose pet is deteriorating?

Use plain language that separates the transfusion from an allergic reaction. Explain that the patient's heart or kidneys could not handle the volume of fluid being given, so fluid backed up into the lungs. State clearly that the transfusion was appropriate but the patient's cardiovascular reserve was insufficient. Describe the immediate plan, including oxygen, diuretics, and monitoring, and give an honest prognosis based on the severity of underlying disease. Avoid language that implies fault or negligence. The MSD Veterinary Manual provides accessible descriptions of circulatory overload that can help you frame the explanation in terms owners can understand.

Does TACO occur in cats receiving xenotransfusions of canine blood?

Yes, and the risk profile differs from dogs. A retrospective review of cats receiving canine packed red blood cells reported transfusion reactions in 43% of cases, with transfusion-associated circulatory overload documented among the recorded reactions alongside acute hemolysis and febrile reactions. The study authors noted that many cats with acute hemolysis did not meet the formal definition of an acute hemolytic transfusion reaction, which complicates reaction classification in this setting. Cats receiving xenotransfusions should be monitored with the same vigilance for volume overload as dogs, and the additional immunologic risks of xenotransfusion should be factored into product selection and monitoring intensity. See the institutional report on xenotransfusion reactions in cats for details.

What do I do when the ideal monitoring equipment is unavailable?

Use serial physical examination as your primary monitoring tool. Measure respiratory rate and effort, auscult the lungs for crackles, assess jugular venous distension, and track body weight before and after transfusion. A weight gain of more than 2% during transfusion supports volume overload. Capillary refill time, mucous membrane color, and pulse quality help distinguish cardiogenic pulmonary edema from other causes of respiratory distress. If a Doppler blood pressure monitor exists, use it to trend mean arterial pressure. The RECOVER Initiative guidelines emphasize that structured assessment and early recognition of deterioration matter more than the sophistication of available equipment.

How should I counsel a colleague who is reluctant to use diuretics in a hypotensive transfused patient?

Acknowledge that diuretic therapy in a hypotensive patient carries genuine risk of worsening perfusion. Frame the decision around the dominant threat: pulmonary edema causing hypoxemia can be immediately life-threatening, whereas moderate hypotension may be tolerated transiently. Recommend a low initial diuretic dose with frequent reassessment of perfusion parameters, and prepare to support blood pressure with judicious crystalloid or colloid administration if needed. Note that the evidence base for diuretic dosing in veterinary TACO is limited, and current formulary references should guide drug selection. The two-hit animal model literature supports the concept that volume-incompliant patients respond differently to transfusion than to crystalloid, which argues for individualised instead of protocolised fluid and diuretic management.

Related Clinical & Scientific Guides

• Toxicology in Emergency Practice: Common Poisons and Diagnostic Approach
• Veterinary Cardiopulmonary Resuscitation: Post-Cardiac Arrest Care
• Fluid Therapy Guidelines for Dogs and Cats: A Practical Update

References and Further Reading

• Incidence of acute hemolysis in cats receiving canine packed red blood cells (xenotransfusions).. 2022.
• An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions.. 2010.
• Volume incompliance and transfusion are essential for transfusion-associated circulatory overload: a novel animal model.. 2019.
• Duration of deep hypothermia during aortic surgery and the risk of perioperative blood transfusion.. 2012.
• Preceding hemorrhagic shock as a detrimental risk factor for respiratory distress after excessive allogeneic blood transfusion.. 2018.
• Can volume-reduced plasma products prevent transfusion-associated circulatory overload in a two-hit animal model?. 2023.
• RECOVER Initiative Veterinary CPR Guidelines. Veterinary Emergency and Critical Care Society.
• AAHA/AAFP Fluid Therapy Guidelines for Dogs and Cats. AAHA.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Veterinary Blood Transfusion Reactions: Recognition and Management
• Veterinary Septic Shock: Recognition and Early Management
• Complication Recognition in Canine Blood Transfusion Reactions
• Veterinary Blood Transfusion: Administration and Monitoring
• Veterinary Blood Transfusion: Blood Types and Crossmatching

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.